Research Topics
| S FernyakSummaryAffiliation: University of California Country: USA Publications
| Collaborators
|
Detail Information
Publications
The cost-effectiveness of expanded HIV counselling and testing in primary care settings: a first lookK A Phillips
School of Pharmacy, University of California, San Francisco, USA
AIDS 14:2159-69. 2000..To estimate the cost-effectiveness of approaches to expanded HIV counselling and testing...- A systematic review of cost-effectiveness analyses of pharmacogenomic interventionsKathryn A Phillips
School of Pharmacy, Institute of Health Policy Studies and UCSF Comprehensive Cancer Center, University of California, San Francisco, 3333 California St, UCSF BOX 0613, San Francisco, CA 94143, USA
Pharmacogenomics 5:1139-49. 2004..Further analyses that can be used to guide the use of pharmacogenomics in clinical practice and in developing health policies are urgently needed... - Willingness to use instant home HIV tests: data from the California Behavioral Risk Factor Surveillance SurveyKathryn A Phillips
sSchool of Pharmacy and Institute of Health Policy Studies, University of California San Francisco, 3333 California Street, Suite 420, Box 0613, San Francisco, CA 94143, USA
Am J Prev Med 24:340-8. 2003..The objective of this study was to examine willingness to use instant home HIV tests and what test characteristics are most important to individuals... - An introduction to cost-effectiveness and cost-benefit analysis of pharmacogenomicsKathryn A Phillips
School of Pharmacy, Institute for Health Policy Studies, and UCSF Comprehensive Cancer Center, University of California, San Francisco, 3333 California Street 420 Box 0613, San Francisco, CA 94143, USA
Pharmacogenomics 4:231-9. 2003..We discuss the steps in conducting a cost-effectiveness or cost-benefit analysis, demonstrating these steps using specific examples from the pharmacogenomics literature... - New Centers for Disease Control and Prevention's guidelines on HIV counseling and testing for the general population and pregnant womenKathryn A Phillips
University of California at San Francisco, San Francisco, California 94143, USA
J Acquir Immune Defic Syndr 32:182-91. 2003..testing and patients accept counseling and testing, obtain their test results, seek treatment, and change risky behaviors? 4) Will the guidelines be relatively cost-effective? 5) Will the guidelines be compatible with ethical standards?.. - Genetic testing and pharmacogenomics: issues for determining the impact to healthcare delivery and costsKathryn A Phillips
Program in Pharmacogenomics and Population Screening, School of Pharmacy, Institute for Health Policy Studies, and UCSF Comprehensive Cancer Center, University of California, San Francisco, 94143, USA
Am J Manag Care 10:425-32. 2004..To determine the potential impact of genetic testing and pharmacogenomics on healthcare delivery and costs... - Important step forward in HIV-testing technologies [correction of technolgies]Kathryn A Phillips
UCSF School of Pharmacy, Institute for Health Policy Studies, University of California-San Francisco, 3333 California Street, Box 0613, San Francisco, CA 94143, USA
Am J Prev Med 25:167. 2003 - Prescription drug dispensing limits and patternsKathryn A Phillips
Health Economics and Health Services Research, School of Pharmacy, Institute for Health Policy Studies, University of California, San Francisco 94143, USA
Manag Care Interface 18:41-6. 2005..Prescription dispensing patterns may have important influences on adherence, therapeutic and preventive health outcomes, and costs. This study examined dispensing patterns for five drug classes commonly prescribed for chronic conditions... - Impact of the U.S. panel on cost-effectiveness in health and medicineKathryn A Phillips
School of Pharmacy and Institute for Health Policy Studies, University of California, San Francisco, CA 94143, USA
Am J Prev Med 22:98-105. 2002..To examine whether recommendations made by the U.S. Panel on Cost-Effectiveness in Health and Medicine (Panel Report) have been associated with changes in how cost-effectiveness analyses are conducted... - Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic reviewK A Phillips
School of Pharmacy, Institute for Health Policy Studies, and Center for AIDS Prevention Studies, University of California, San Francisco, 3333 California St, Room 420, Box 0613, San Francisco, CA 94143, USA
JAMA 286:2270-9. 2001.... - Health and economic benefits of increased beta-blocker use following myocardial infarctionK A Phillips
School of Pharmacy and Institute for Health Policy Studies, University of California, San Francisco, 3333 California St, Room 420, Box 0613, San Francisco, CA 94143, USA
JAMA 284:2748-54. 2000..Understanding the consequences of underuse of beta-blockers is important because of the implications for current policy debates over quality-of-care measures and Medicare prescription drug coverage... - Patient costs for medication abortion: results from a study of five clinical practicesStephanie L Van Bebber
Advancing New Standards in Reproductive Health program, Center for Reproductive Health Research and Policy, San Francisco, California, USA
Womens Health Issues 16:4-13. 2006..We should continue to develop our knowledge of the clinical and nonclinical trade-offs for women choosing between abortion methods to benefit patient decision making... 
Moving beyond the typologies of managed care: the example of health plan predictors of screening mammographySherilyn Tye
School of Pharmacy, University of California, San Francisco 94143, USA
Health Serv Res 39:179-206. 2004....- Cost-effectiveness analysis of genetic testing for familial long QT syndrome in symptomatic index casesKathryn A Phillips
School of Pharmacy, Institute for Health Policy Studies, and UCSF Comprehensive Cancer Center, University of California, San Francisco, 94143, USA
Heart Rhythm 2:1294-300. 2005..Genetic testing for long QT syndrome (LQTS) has been available in a research setting for the past decade, and a commercial test has recently become available. However, the costs and effectiveness of genetic testing have not been estimated... - Colorectal cancer screening differential costs for younger versus older AmericansUri Ladabaum
Division of Gastroenterology, University of California San Francisco, 94143 0538, USA
Am J Prev Med 30:378-84. 2006..It was therefore hypothesized that increased use of CRC screening and polypectomy in younger persons might yield CRC-related savings later in life for payers such as Medicare... - Regulatory perspectives on pharmacogenomics: a review of the literature on key issues faced by the United States Food and Drug AdministrationKathryn A Phillips
University of California, San Francisco, CA 94143, USA
Med Care Res Rev 63:301-26. 2006..This review identifies issues faced by the FDA with respect to PGx, which the FDA is addressing through several initiatives. It also illustrates the complex issues involved in developing, implementing, and adopting new technologies... - Diagnostics and biomarker development: priming the pipelineKathryn A Phillips
School of Pharmacy, Institute for Health Policy Studies, and University of California San Francisco, 3333 California Street, Room 420, UCSF BOX 0613, San Francisco, California 94143, USA
Nat Rev Drug Discov 5:463-9. 2006..Here, we characterize the pipeline problem for biomarkers and diagnostics, and consider what steps could be taken to solve it... 
A review of studies examining stated preferences for cancer screeningKathryn A Phillips
University of California, San Francisco, San Francisco, CA 94143 0613, USA
Prev Chronic Dis 3:A75. 2006..Our objectives were to conduct a systematic review of stated preference studies for cancer screening, identify gaps in the literature, and determine which types of research should be conducted in the future...- The intersection of biotechnology and pharmacogenomics: health policy implicationsKathryn A Phillips
School of Pharmacy, Institute for Health Policy Studies, and Comprehensive Cancer Center at the University of California, San Francisco, USA
Health Aff (Millwood) 25:1271-80. 2006..Key policy challenges include determining the appropriate role of policy in (1) providing incentives to develop socially beneficial interventions and (2) facilitating development of the evidence base... - Rates and predictors of colorectal cancer screeningSu Ying Liang
School of Pharmacy, University of California, San Francisco, 3333 California St, Suite 420, Box 0613, San Francisco, CA 94143, USA
Prev Chronic Dis 3:A117. 2006.... - Provider practice models for and costs of delivering medication abortion -- evidence from 11 US abortion care settingsAimee Afable-Munsuz
University of California, San Francisco and Advancing New Standards in Reproductive Health ANSIRH program, Bixby Center for Reproductive Health Research and Policy, San Francisco, CA 94143, USA
Contraception 75:45-51. 2007..This study provides descriptive data on the diverse MAB practice models currently being utilized by US health care providers and the costs associated with the components of those models... - Trends in colonoscopy for colorectal cancer screeningKathryn A Phillips
University of California, San Francisco, CA 94143, USA
Med Care 45:160-7. 2007..A major health priority is to increase colorectal cancer screening, and colonoscopy has become an increasingly important method of screening. The Medicare program began coverage for colonoscopy for average risk individuals in 2001... - Challenges to the translation of genomic information into clinical practice and health policy: Utilization, preferences and economic valueKathryn A Phillips
University of California at San Francisco, Department of Clinical Pharmacy, School of Pharmacy, Institute for Health Policy Studies, and UCSF Comprehensive Cancer Center, San Francisco, CA 94143 USA
Curr Opin Mol Ther 10:260-6. 2008..Major challenges include a lack of linked data, the need for relevant research frameworks and methodologies, and the clinical complexities of genomic-based diagnostics and treatment... - Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patientsKathryn A Phillips
Department of Clinical Pharmacy, University of California San Francisco, San Francisco, CA 94143 0613, USA
Cancer 115:5166-74. 2009..Human epidermal growth factor receptor 2 (HER2) testing to target trastuzumab for patients with breast cancer provides insights into the evidence needed for emerging testing technologies... - A qualitative study of insurers' coverage for mifepristone-induced abortionMarcel P Gemperli
SCF, San Francisco, California 94143 1744, USA
Manag Care Interface 18:26-30, 32. 2005..A model coverage policy that contains comprehensive clinical information regarding appropriate clinical regimens for mifepristone is provided as an example for insurers and others in the field... - Does patient cost sharing matter? Its impact on recommended versus controversial cancer screening servicesSu Ying Liang
University of California, 3333 California St, Suite 420, Box 0613, San Francisco, CA 94143, USA
Am J Manag Care 10:99-107. 2004.... - Effect of managed care insurance on the use of preventive care for specific ethnic groups in the United StatesJennifer S Haas
Institute for Health Policy Studies, Division of General Internal Medicine, San Francisco General Hospital, CA, USA
Med Care 40:743-51. 2002..Despite the broad implementation of managed care, there is little information that specifically addresses how this type of coverage may affect ethnic disparities... - Are gatekeeper requirements associated with cancer screening utilization?Kathryn A Phillips
School of Pharmacy, Institute of Health Policy Studies, UCSF Comprehensive Cancer Center, University of California, San Francisco 94143, USA
Health Serv Res 39:153-78. 2004..Our objective was to examine whether gatekeeper requirements are associated with the utilization of cancer screening for breast, cervical, and prostate cancer... - Variation in screening mammography and Papanicolaou smear by primary care physician specialty and gatekeeper plan (United States)David A Haggstrom
San Francisco General Hospital, Division of General Internal Medicine, University of California, San Francisco
Cancer Causes Control 15:883-92. 2004..To assess whether the specialty of a patient's primary care physician or being part of a gatekeeper plan influence breast and cervical cancer screening... - Measuring preferences for health care interventions using conjoint analysis: an application to HIV testingKathryn A Phillips
School of Pharmacy, Institute for Health Policy Studies, and Center for AIDS Prevention Studies, University of California-San Francisco, 94143, USA
Health Serv Res 37:1681-705. 2002..Conjoint analysis offers an approach that can be useful for measuring and understanding the value of other health care goods, services, and interventions... - Measuring what people value: a comparison of "attitude" and "preference" surveysKathryn A Phillips
School of Pharmacy, Institute for Health Policy Studies, and Center for AIDS Prevention Studies, University of California-San Francisco, 94143, USA
Health Serv Res 37:1659-79. 2002..Health researchers should consider the advantages and limitations of both methods when determining how to measure what people value... - Is the prevalence of gatekeeping in a community associated with individual trust in medical care?Jennifer S Haas
Institute for Health Policy Studies, University of California, San Francisco, USA
Med Care 41:660-8. 2003..Consumer concerns about the restrictions of managed care may lead to distrust... - Out-of-pocket expenditures for oral contraceptives and number of packs per purchaseKathryn A Phillips
School of Pharmacy and the Institute for Health Policy Studies, University of California, San Francisco, USA
J Am Med Womens Assoc 59:36-42. 2004..CONCLUSION: Out-of-pocket costs and dispensing restrictions may be barriers to consistent use of OCPs. Women's health care providers should consider options to overcome these barriers, such as the use of mail order prescription services... - Willingness to recommend a health plan: who is dissatisfied and what don't they like?Julie A Sakowski
Department of Psychiatry, University of California San Francisco, Calif, USA
Am J Manag Care 10:393-400. 2004.... - Measuring managed care and its environment using national surveys: a review and assessmentSu-Ying Liang
University of California, San Francisco, USA
Med Care Res Rev 63:9S-36S. 2006.... - Measuring the value of pharmacogenomicsKathryn A Phillips
School of Pharmacy and Institute for Health Policy Studies, University of California, San Francisco, 3333 California Street, Box 0613, San Francisco, California 94143, USA
Nat Rev Drug Discov 4:500-9. 2005..This review provides a framework for analysing the value of pharmacogenomic interventions, and suggests where further research and development could be most beneficial... - Angiotensin receptor blockers on the formularies of Medicare drug plansWalid F Gellad
Division of General Medicine and Primary Care, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 1620 Tremont Street, Boston, MA 02120 1613, USA
J Gen Intern Med 22:1172-5. 2007..The presence of angiotensin receptor blockers (ARBs) on the formularies of Medicare Part D prescription drug plans (PDPs) is vitally important to the health of seniors who cannot tolerate angiotensin-converting enzyme (ACE) inhibitors... - Association of regional variation in primary care physicians' colorectal cancer screening recommendations with individual use of colorectal cancer screeningJennifer S Haas
Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02120 1613, USA
Prev Chronic Dis 4:A90. 2007..However, another possible influence, the effect of regional differences in physicians' beliefs and recommendations on screening use, has not been assessed... - Measuring patient preferences for colorectal cancer screening using a choice-format surveyDeborah A Marshall
McMaster University, Hamilton, ON, Canada
Value Health 10:415-30. 2007..Our objective is to examine patient preferences for CRC screening modalities and uptake rates using utility-based methods... - The effect of area HMO market share on cancer screeningLaurence C Baker
Department of Health Research and Policy, Stanford University School of Medicine, Stanford, CA, USA
Health Serv Res 39:1751-72. 2004..Neither the level of competition between area HMOs nor area PPO market share is associated with screening rates. CONCLUSIONS: Area-level managed care activity can influence preventive care treatment patterns... - The association of race, socioeconomic status, and health insurance status with the prevalence of overweight among children and adolescentsJennifer S Haas
Division of General Medicine, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
Am J Public Health 93:2105-10. 2003..We examined the effect of race, socioeconomic status, and health insurance status on the prevalence of overweight among children and adolescents... - An experiment on simplifying conjoint analysis designs for measuring preferencesTara Maddala
Clinimetrics Research Inc, San Jose, California, USA
Health Econ 12:1035-47. 2003..However, evidence suggested that there were differences in stated preferences. The results increase our understanding of how respondents answer CA questions and how to improve future surveys... - How the new medicare drug benefit could affect vulnerable populationsWalid F Gellad
Department of Medicine, Brigham and Women's Hospital, in Boston, MA, USA
Health Aff (Millwood) 25:248-55. 2006.... - Biotechnology and Medicare's new technology policy: lessons from three case studiesPatricia Seliger Keenan
Division of Health Policy and Administration, Department of Epidemiology and Public Health, Yale University School of Medicine in New Haven, Connecticut, USA
Health Aff (Millwood) 25:1260-9. 2006..The cases suggest Medicare's ongoing challenge to balance access considerations, the role and strength of evidence, and cost consequences of new treatments... - Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000Jennifer S Haas
Brigham and Women s Hospital, Division of General Medicine and Primary Care, Boston, Massachusetts 02120, USA
Ann Intern Med 142:891-7. 2005..Generic substitution is one mechanism of curtailing prescription drug expenditures. Limited information is available about the potential savings associated with generic substitution... - Variation in access to health care for different racial/ethnic groups by the racial/ethnic composition of an individual's county of residenceJennifer S Haas
Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusett 02160, USA
Med Care 42:707-14. 2004.... - Viagra and contraceptivesKathryn A Phillips
Health Aff (Millwood) 22:277. 2003 - Drug withdrawals in the United States: a systematic review of the evidence and analysis of trendsAmalia M Issa
Program in Personalized Medicine and Targeted Therapeutics, University of Houston, 300 Technology Building, Houston, TX 77204 4021, USA
Curr Drug Saf 2:177-85. 2007..A comprehensive approach will be needed to address the improvement of drug safety. We propose improvements to the evidence base to increase drug safety and assess how new scientific evidence can be incorporated into drug safety efforts...